Paper Details

  1. Home
  2. Paper Details

Angiotensin-converting enzyme inhibition in mild hypertension with concomitant diseases and therapies: an efficacy, safety, and compatibility study of novel design, the Perindopril Therapeutic Safety Study.

Author: OverlackA, StumpeK O

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Perindopril, an angiotensin-converting enzyme (ACE) inhibitor, is being studied in a novel clinical trial to determine its safety and efficacy in patients with hypertension and eight common concomitant diseases. The study, the Perindopril Therapeutic Safety Study, is ongoing and involves a 6-week double-blind phase followed by a 1-year follow-up period. Initial results suggest that this design is feasible and promising.
Paper Details　
Original Abstract of the Article :
Despite a marked reduction in cardiovascular morbidity and mortality, treated hypertensive patients remain at increased risk of coronary artery disease and its complications compared with untreated normotensive subjects. Mild hypertension is often associated with other, usually chronic, diseases. Th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0002-9343(92)90157-7

データ提供：米国国立医学図書館（NLM）

ACE Inhibition: A Multifaceted Approach to Managing Hypertension and Concomitant Diseases

Hypertension, like a relentless desert wind, can silently erode our health. This study investigates the efficacy and safety of angiotensin-converting enzyme (ACE) inhibition in managing hypertension, particularly in patients with concomitant diseases. The authors design a unique study to assess the interaction of ACE inhibition with eight common coexisting conditions and their respective therapies.

ACE Inhibition: A Promising Approach for Managing Multiple Health Challenges

The study involves 480 patients with mild hypertension and one or more of the following conditions: hyperlipidemia, type II diabetes, ischemic heart disease, cardiac arrhythmia, peripheral arterial disease, nephropathy with proteinuria, chronic obstructive lung disease, or rheumatoid arthritis. The researchers assess the impact of ACE inhibition on blood pressure, concomitant disease progression, and interactions with other therapies. The study's novel design allows for a comprehensive evaluation of the benefits and risks of ACE inhibition in a diverse patient population.

Tailoring Treatment for Hypertension: Addressing Individual Needs

This research highlights the importance of individualizing treatment approaches for hypertension, particularly in patients with multiple health challenges. By understanding the potential interactions between ACE inhibitors and other therapies, healthcare providers can optimize treatment regimens, ensuring effective management of hypertension and minimizing the risk of adverse effects.

Dr.Camel's Conclusion

The desert of hypertension management is often characterized by a complex interplay of factors. This study offers a promising new approach, exploring the efficacy and safety of ACE inhibition in a diverse population. By carefully considering the individual needs of patients and the potential interactions with other medications, we can navigate this challenging terrain, improving health outcomes and promoting well-being.

Date :
  1. Date Completed 1992-06-05
  2. Date Revised 2019-06-26
Further Info :

Pubmed ID

1580290

DOI: Digital Object Identifier

10.1016/0002-9343(92)90157-7

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.